CN102512416A - Medicine composition containing dehydrogenated corydaline as well as preparation method and measurement method - Google Patents
Medicine composition containing dehydrogenated corydaline as well as preparation method and measurement method Download PDFInfo
- Publication number
- CN102512416A CN102512416A CN201110372556XA CN201110372556A CN102512416A CN 102512416 A CN102512416 A CN 102512416A CN 201110372556X A CN201110372556X A CN 201110372556XA CN 201110372556 A CN201110372556 A CN 201110372556A CN 102512416 A CN102512416 A CN 102512416A
- Authority
- CN
- China
- Prior art keywords
- dehydrocorydaline
- corydaline
- preparation
- quaternary ammonium
- dehydrogenated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine composition containing dehydrogenated corydaline as well as a preparation method and a measurement method. The medicine composition is a composition which is mainly prepared by a method for extracting a medicinal material of corydalis tuber through the thermal refluxing of ethanol and purifying the corydalis tuber by macroporous adsorptive resin, and comprises dehydrogenated corydaline, total quaternary ammonium hydroxide, columbamine, 13-methyldehydrocorydalmine, dehydrocorybulbine and palmatine, wherein the content of the dehydrogenated corydaline, which is measured by using a high-efficiency liquid chromatography method, is not lower than 10 percent; the content of the total quaternary ammonium hydroxide in the composition, which is calculated according to the dehydrogenated corydaline, is not lower than 50 percent; and the measurement method comprises a measurement method to the dehydrogenated corydaline and a measurement method to the total quaternary ammonium hydroxide of the corydalis tuber. The medicine composition containing the dehydrogenated corydaline as well as the preparation method and the measurement method have the characteristics of simple production process, short production period, high safety, no pollution to the environment, low cost, high yield and the like, and are especially suitable for industrialized mass production; and the medicine composition containing the dehydrogenated corydaline can be used for lowering the degree of myocardial infarction and has the functions of obviously resisting myocardial ischemia and obviously prolonging the anoxia-proof time of a rat.
Description
Technical field
The present invention relates to the pharmaceutical composition of a kind of resisting myocardial ischemia and anoxia enduring; Specifically; Be dehydrocorydaline and mainly contain the application in preparation treatment resisting myocardial ischemia and anoxia enduring medicine such as Columbamine, 13-methyl dehydrocorydalmine, dehydrotetrahydropulmatine, palmatine, belong to medical technical field.
Background technology
Rhizoma Corydalis (Corydalis yanhusuo W.T.Wang) practise to be claimed Rhizoma Corydalis, and the beginning is stated from supplement to the Herbal, has promoting the circulation of QI to relieve pain, the effect of blood circulation promoting and blood stasis dispelling, in Chinese medicine and pharmacy for traditional invigorate blood circulation, circulation of qi promoting, analgesic.What the chemical constituent of Rhizoma Corydalis was found at present mainly is alkaloid; Character by its amino nitrogen then can be divided into tertiary amine base and quaternary ammonium base two big classes; So far mostly the alkaloid of from its tuber, finding altogether is the tertiary amine base constituents, and to the research of quaternary ammonium base composition understatement road still.
Experimentation shows that the character of alkaloidal pharmacological action and its amino nitrogen is closely related in the Rhizoma Corydalis, and wherein the tertiary amine bases shows analgesia, calm and stable effect more; And Rhizoma Corydalis mainly is the existence because of the quaternary ammonium base constituents in the remarkable effect of aspects such as resisting myocardial ischemia, minimizing myocardium keto consumption.265), but the composition of clear and definite Rhizoma Corydalis total alkaloids not Qiu Rongli etc. once carried out experimentation (Chinese Chinese medicine science and technology, 2001,8 (4): to the Rhizoma Corydalis total alkaloids function of resisting myocardial ischemia.Up to the present, also there are not bibliographical information dehydrocorydaline and compositions to have resisting myocardial ischemia and resisting oxygen lack.We have carried out resisting myocardial ischemia and anoxia enduring experiment to quaternary ammonium total alkalis in the Rhizoma Corydalis (being mainly dehydrocorydaline and compositions) as effective ingredient, and have had good pharmacological action on the basis of searching document and patent.
Do not find the research report of relevant dehydrocorydaline and compositions resisting myocardial ischemia and anoxia enduring before the present invention accomplishes, do not find that dehydrocorydaline reaches the application that the compositions that mainly contains Columbamine, 13-methyl dehydrocorydalmine, dehydrotetrahydropulmatine, palmatine etc. is used for treating resisting myocardial ischemia and anoxia enduring medicine yet.
Summary of the invention
It is a kind of at the pharmaceutical composition that contains dehydrocorydaline that good pharmacological action is all arranged aspect resisting myocardial ischemia and the anoxia enduring and method for preparing and assay method that the object of the invention provides.
The objective of the invention is to accomplish through following technical scheme; A kind of pharmaceutical composition that contains dehydrocorydaline; It mainly is that corydalis tuber medicinal material is extracted through alcohol heat reflux; The purification with macroreticular resin method makes the compositions of being made up of dehydrocorydaline and quaternary ammonium total alkalis, Columbamine, 13-methyl dehydrocorydalmine, dehydrotetrahydropulmatine, palmatine, and wherein, the content of dehydrocorydaline records with HPLC and is not less than 10%; Contain quaternary ammonium total alkalis in the compositions and be not less than 50% in dehydrocorydaline.
Described compositions contains quaternary ammonium total alkalis 57.40%, and wherein dehydrocorydaline 14.05%, Columbamine 4.06%, 13-methyl dehydrocorydalmine 1.34%, dehydrotetrahydropulmatine 3.99%, palmatine 4.10%.
A kind of preparation of drug combination method that contains dehydrocorydaline as stated, this method is: select corydalis tuber medicinal material for use, through pulverizing, add 12-16 and doubly measure 80% alcohol reflux 3 times; Each 3-5 hour, merge extractive liquid, filtered and removes medicinal residues, and filtrate recycling ethanol is to there not being the alcohol flavor; Medicinal liquid suitably dilutes with deionized water, and through X-5 type macroporous adsorbent resin, medicinal liquid adsorbs through resin column, and flow velocity is the 1-3 ml/min; After absorption finished, earlier with the non-adsorbable impurity of 2% ammonia spirit flush away, reuse 50% alcoholic solution eluting was collected alcohol eluen; With the eluent concentrating under reduced pressure, vacuum drying below 60 ℃, dry thing reuse 95% ethanol redissolves; Filter, filtrating is reclaimed solvent to doing, and must contain the dehydrocorydaline compositions.
The said corydalis tuber medicinal material of selecting for use through pulverizing, adds 14 times of amount 80% alcohol refluxs and extracts each 4 hours respectively 3 times by 6 times, 4 times, 4 times; Described as to contain in the dehydrocorydaline compositions, contain quaternary ammonium total alkalis 57.40%, wherein dehydrocorydaline 14.05%, Columbamine 4.06%, 13-methyl dehydrocorydalmine 1.34%, dehydrotetrahydropulmatine 3.99%, palmatine 4.10%.
A kind of dehydrocorydaline assay method that contains the pharmaceutical composition of dehydrocorydaline as stated, it is to utilize high effective liquid chromatography for measuring, comprising: be filler with the octadecylsilane chemically bonded silica; With acetonitrile-water (containing 0.8% glacial acetic acid and 0.2% triethylamine) (24: 76) is mobile phase; The detection wavelength is 335nm; Number of theoretical plate calculates by the dehydrocorydaline peak and is not less than 3000;
The preparation of reference substance solution: precision takes by weighing the dehydrocorydaline reference substance, and each is an amount of, and using dissolve with methanol to process concentration is 126.88 μ g/mL reference substance solution;
The preparation of need testing solution: get compositions 10mg, accurate claim fixed, with 80% dissolve with methanol and standardize solution in the 10mL measuring bottle, as need testing solution;
Assay method: accurate respectively reference substance solution and each 10 μ L of need testing solution of drawing, inject chromatograph of liquid, measure, promptly get.
A kind of Rhizoma Corydalis quaternary ammonium total alkali assay method that contains the pharmaceutical composition of dehydrocorydaline as stated, it is to utilize following ultraviolet colorimetric method for determining, comprising:
The preparation of reference substance solution: it is an amount of to get dehydrocorydaline, adds dissolve with methanol, is mixed with the 0.1mg/mL reference substance solution;
The preparation of need testing solution: it is an amount of to get compositions, adds 80% methanol ultrasonic dissolution, is mixed with the 0.2mg/mL need testing solution;
Assay method: accurate respectively reference substance solution, each 0.5mL of need testing solution of drawing, add pH8 phosphate buffer 5mL, bromothymol blue test solution 1mL adds chloroform 6mL again; Close plug, shaken 2min are transferred in the separatory funnel, leave standstill 1h; Obtain chloroform layer in the test tube that is placed with the 0.1g anhydrous sodium sulfate, after jolting is left standstill, obtain the upper strata chloroform; With the blank is contrast, measures absorbance in the 415nm place, calculates.
Characteristics of the present invention are that after Rhizoma Corydalis extracted with aquiferous ethanol, extracting solution through the macroporous adsorptive resins purification, can not obtain the high-load compositions that contains dehydrocorydaline after not concentrating and directly reclaiming solvent; Whole production technology is only used the second alcohol and water, does not use inflammable and explosive and toxic solvent, and production technology is simple, and is with short production cycle, and safety is free from environmental pollution, and cost is low, and yield is high, is particularly suitable for the industrialization mass production; The present invention can reduce the myocardial infarction degree, has tangible resisting myocardial ischemia and the effect that obviously prolongs the mice hypoxia endurance time.
The specific embodiment
To combine specific embodiment that the present invention is done detailed introduction below: a kind of pharmaceutical composition that contains dehydrocorydaline of the present invention; It mainly is that corydalis tuber medicinal material is extracted through alcohol heat reflux; The purification with macroreticular resin method makes the compositions of being made up of dehydrocorydaline and quaternary ammonium total alkalis, Columbamine, 13-methyl dehydrocorydalmine, dehydrotetrahydropulmatine, palmatine; Wherein, the content of dehydrocorydaline records with HPLC and is not less than 10%; Contain quaternary ammonium total alkalis in the compositions and be not less than 50% in dehydrocorydaline.
Described compositions contains quaternary ammonium total alkalis 57.40%, and wherein dehydrocorydaline 14.05%, Columbamine 4.06%, 13-methyl dehydrocorydalmine 1.34%, dehydrotetrahydropulmatine 3.99%, palmatine 4.10%.
A kind of preparation of drug combination method that contains dehydrocorydaline as stated, this method is: select corydalis tuber medicinal material for use, through pulverizing, add 12-16 and doubly measure 80% alcohol reflux 3 times; Each 3-5 hour, merge extractive liquid, filtered and removes medicinal residues, and filtrate recycling ethanol is to there not being the alcohol flavor; Medicinal liquid suitably dilutes with deionized water, and through X-5 type macroporous adsorbent resin, medicinal liquid adsorbs through resin column, and flow velocity is the 1-3 ml/min; After absorption finished, earlier with the non-adsorbable impurity of 2% ammonia spirit flush away, reuse 50% alcoholic solution eluting was collected alcohol eluen; With the eluent concentrating under reduced pressure, vacuum drying below 60 ℃, dry thing reuse 95% ethanol redissolves; Filter, filtrating is reclaimed solvent to doing, and must contain the dehydrocorydaline compositions.
The said corydalis tuber medicinal material of selecting for use through pulverizing, adds 14 times of amount 80% alcohol refluxs and extracts each 4 hours respectively 3 times by 6 times, 4 times, 4 times; Described as to contain in the dehydrocorydaline compositions, contain quaternary ammonium total alkalis 57.40%, wherein dehydrocorydaline 14.05%, Columbamine 4.06%, 13-methyl dehydrocorydalmine 1.34%, dehydrotetrahydropulmatine 3.99%, palmatine 4.10%.
Embodiment of the present invention can choose arbitrarily and make up in above-mentioned selected scope, and constitutes multiple embodiments of the present invention, disclosed a certain embodiment after being not limited to.
A kind of dehydrocorydaline assay method that contains the pharmaceutical composition of dehydrocorydaline as stated, it is to utilize high effective liquid chromatography for measuring, comprising: be filler with the octadecylsilane chemically bonded silica; With acetonitrile-water (containing 0.8% glacial acetic acid and 0.2% triethylamine) (24: 76) is mobile phase; The detection wavelength is 335nm; Number of theoretical plate calculates by the dehydrocorydaline peak and is not less than 3000;
The preparation of reference substance solution: precision takes by weighing the dehydrocorydaline reference substance, and each is an amount of, and using dissolve with methanol to process concentration is 126.88 μ g/mL reference substance solution;
The preparation of need testing solution: get compositions 10mg, accurate claim fixed, with 80% dissolve with methanol and standardize solution in the 10mL measuring bottle, as need testing solution;
Assay method: accurate respectively reference substance solution and each 10 μ L of need testing solution of drawing, inject chromatograph of liquid, measure, promptly get.
A kind of Rhizoma Corydalis quaternary ammonium total alkali assay method that contains the pharmaceutical composition of dehydrocorydaline as stated, it is to utilize following ultraviolet colorimetric method for determining, comprising:
The preparation of reference substance solution: it is an amount of to get dehydrocorydaline, adds dissolve with methanol, is mixed with the 0.1mg/mL reference substance solution;
The preparation of need testing solution: it is an amount of to get compositions, adds 80% methanol ultrasonic dissolution, is mixed with the 0.2mg/mL need testing solution;
Assay method: accurate respectively reference substance solution, each 0.5mL of need testing solution of drawing, add pH8 phosphate buffer 5mL, bromothymol blue test solution 1mL adds chloroform 6mL again; Close plug, shaken 2min are transferred in the separatory funnel, leave standstill 1h; Obtain chloroform layer in the test tube that is placed with the 0.1g anhydrous sodium sulfate, after jolting is left standstill, obtain the upper strata chloroform; With the blank is contrast, measures absorbance in the 415nm place, calculates.
Embodiment:
1, contains the extraction preparation of dehydrocorydaline compositions
Corydalis tuber medicinal material is pulverized, add 14 times of amount 80% alcohol reflux 3 times (6 times, 4 times, 4 times); Each 4 hours, merge extractive liquid, filtered and removes medicinal residues, and filtrate recycling ethanol is not to there being the alcohol flavor, and medicinal liquid suitably dilutes with deionized water; Through X-5 type macroporous adsorbent resin, medicinal liquid adsorbs through resin column, and flow velocity is 2 ml/min, after absorption finishes, earlier with the non-adsorbable impurity of 2% ammonia spirit flush away; Reuse 50% alcoholic solution eluting is collected alcohol eluen, with the eluent concentrating under reduced pressure, and vacuum drying below 60 ℃; Dry thing reuse 95% ethanol redissolves, and filters, and filtrating is reclaimed solvent to doing, and must contain the dehydrocorydaline compositions.This compositions contains quaternary ammonium total alkalis 57.40%, and wherein dehydrocorydaline 14.05%, Columbamine 4.06%, 13-methyl dehydrocorydalmine 1.34%, dehydrotetrahydropulmatine 3.99%, palmatine 4.10%.
2, the experiment of pharmaceutical composition resisting myocardial ischemia according to the invention and resisting oxygen lack
2.1 laboratory animal
CD-1/ (ICR) mice, male and female half and half, body weight 18-22g is provided by Beijing Vital River Experimental Animals Technology Co., Ltd., licence numbering: SCXK (capital) 2007-0001.The Wister rat, male, body weight 220-240g is provided by Beijing Vital River Experimental Animals Technology Co., Ltd., licence numbering: SCXK (capital) 2007-0001.
2.2 method and result
2.2.1 isoproterenol is brought out the influence of rat heart muscle ischemia
2.2.1.1 grouping, administration and modeling
Be divided into 6 groups at random through the qualified rat of primary dcreening operation, 8 every group: blank group, model group, administration low dose group, middle dose groups, high dose group and crude extract group.After the experiment beginning, administration low dose group, middle dose groups, high dose group and crude extract group are all irritated stomach by the 10mL/kg body weight and are given relative medicine, and blank and model group are irritated clothes with the volume distilled water, administration every day 1 time, continuous 7 days.From testing beginning in the 5th day, except that blank group lumbar injection with the volume normal saline, all the other each groups are 1h lumbar injection isoproterenol (ISO) injection (5mg/kg) behind gastric infusion all, injects continuously 3 days, interval is 24h.Cause Model Rats with Acute Myocardial Ischemia.
2.2.1.2 detect index and method
2h puts to death rat behind the last injection ISO, and carotid artery is got blood, centrifugal extraction serum.The method that provides by test kit detects Serum LDH, CK, NO activity.Data are represented with X ± S, adopt the t check to carry out significance analysis between group, with the standard of P＜0.05 as significant difference.The result sees table 1.
Table 1 couple ISO bring out rats with myocardial ischemia Serum LDH, CK, NO influence (x ± s, n=8)
Compare with the blank group
#P＜0.05; Compare with model group
*P＜0.05,
*P＜0.01
2.2.2 influence to the normal anoxia in mice time-to-live
Mice is divided into 4 groups at random, 10 every group: blank group, low dosage administration group, middle dosed administration group, high dose administration group.Gastric infusion, for three days on end, 15min after the last administration puts into the wide mouthed bottle that the 250mL bottom fills the 7.5g sodica calx, and is airtight, the record mice death by suffocation time.The result sees table 2.
The influence of table 2 pair normal anoxia in mice time-to-live (x ± s, n=10)
Compare * P＜0.05, * * P＜0.01 with normal group
2.2.3 ISO is brought out the influence of myocardial ischemia anoxia in mice time-to-live
Mice is divided into 7 groups at random, 8 every group: low dosage administration group, middle dosed administration group, high dose administration group, crude extract group, water elution thing group, model group and blank group.Model group and blank group give isometric normal saline.Each organizes continuous gastric infusion 3d, 1h after administration in the 3rd day, equal tail vein injection ISO 2mg/kg except that the blank group.Behind the 15min, put into the wide mouthed bottle that the 250mL bottom fills the 7.5g sodica calx, airtight, the record mice death by suffocation time; The result sees table 3.
Table 3 couple ISO induce the myocardial ischemia mice time-to-live influence (x ± s, n=8)
Compare * P＜0.01 with normal group; Compare with model group
#P＜0.01
More than experiment shows, the effect that pharmaceutical composition according to the invention has the Mus myocardial ischemia effect of the tangible Chinese People's Anti-Japanese Military and Political College and obviously prolongs the mice hypoxia endurance time.
Claims (6)
1. pharmaceutical composition that contains dehydrocorydaline; It mainly is that corydalis tuber medicinal material is extracted through alcohol heat reflux; The purification with macroreticular resin method makes the compositions of being made up of dehydrocorydaline and quaternary ammonium total alkalis, Columbamine, 13-methyl dehydrocorydalmine, dehydrotetrahydropulmatine, palmatine; Wherein, the content of dehydrocorydaline records with HPLC and is not less than 10%; Contain quaternary ammonium total alkalis in the compositions and be not less than 50% in dehydrocorydaline.
2. the pharmaceutical composition that contains dehydrocorydaline according to claim 1; It is characterized in that described compositions contains quaternary ammonium total alkalis 57.40%; Wherein dehydrocorydaline 14.05%, Columbamine 4.06%, 13-methyl dehydrocorydalmine 1.34%; Dehydrotetrahydropulmatine 3.99%, palmatine 4.10%.
3. preparation of drug combination method that contains dehydrocorydaline according to claim 1, this method is: select corydalis tuber medicinal material for use, through pulverizing, adds 12-16 times and measure 80% alcohol reflux 3 times; Each 3-5 hours, merge extractive liquid, filtered and removes medicinal residues, and filtrate recycling ethanol is to there not being the alcohol flavor; Medicinal liquid suitably dilutes with deionized water, and through X-5 type macroporous adsorbent resin, medicinal liquid adsorbs through resin column, and flow velocity is 1-3 ml/min; After absorption finished, earlier with the non-adsorbable impurity of 2% ammonia spirit flush away, reuse 50% alcoholic solution eluting was collected alcohol eluen; With the eluent concentrating under reduced pressure, vacuum drying below 60 ℃, dry thing reuse 95% ethanol redissolves; Filter, filtrating is reclaimed solvent to doing, and must contain the dehydrocorydaline compositions.
4. the preparation of drug combination method that contains dehydrocorydaline according to claim 3 is characterized in that selecting for use corydalis tuber medicinal material, through pulverizing, adds 14 times of amount 80% alcohol refluxs and extracts each 4 hours respectively 3 times by 6 times, 4 times, 4 times; Described as to contain in the dehydrocorydaline compositions, contain quaternary ammonium total alkalis 57.40%, wherein dehydrocorydaline 14.05%, Columbamine 4.06%, 13-methyl dehydrocorydalmine 1.34%, dehydrotetrahydropulmatine 3.99%, palmatine 4.10%.
5. a dehydrocorydaline assay method that contains the pharmaceutical composition of dehydrocorydaline according to claim 1 is characterized in that it is to utilize high effective liquid chromatography for measuring, comprising: be filler with the octadecylsilane chemically bonded silica; With the acetonitrile-water that contains 0.8% glacial acetic acid and 0.2% triethylamine is mobile phase, wherein glacial acetic acid: triethylamine=24:76; Detecting wavelength is 335 nm; Number of theoretical plate calculates by the dehydrocorydaline peak and is not less than 3000;
The preparation of reference substance solution: precision takes by weighing the dehydrocorydaline reference substance, and each is an amount of, and using dissolve with methanol to process concentration is 126.88 μ g/mL reference substance solution;
The preparation of need testing solution: get compositions 10mg, accurate claim fixed, with 80% dissolve with methanol and standardize solution in the 10mL measuring bottle, as need testing solution;
Assay method: accurate respectively reference substance solution and each 10 μ L of need testing solution of drawing, inject chromatograph of liquid, measure, promptly get.
6. Rhizoma Corydalis quaternary ammonium total alkali assay method that contains the pharmaceutical composition of dehydrocorydaline according to claim 1 is characterized in that it utilizes the ultraviolet colorimetric method for determining:
The preparation of reference substance solution: it is an amount of to get dehydrocorydaline, adds dissolve with methanol, is mixed with 0.1 mg/mL reference substance solution;
The preparation of need testing solution: it is an amount of to get compositions, adds 80% methanol ultrasonic dissolution, is mixed with the 0.2mg/mL need testing solution;
Assay method: accurate respectively reference substance solution, each 0.5 mL of need testing solution of drawing, add pH8 phosphate buffer 5mL, bromothymol blue test solution 1mL adds chloroform 6mL again; Close plug, shaken 2min are transferred in the separatory funnel, leave standstill 1h; Obtain chloroform layer in the test tube that is placed with the 0.1g anhydrous sodium sulfate, after jolting is left standstill, obtain the upper strata chloroform; With the blank is contrast, measures absorbance in the 415nm place, calculates.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110372556XA CN102512416A (en) | 2011-11-22 | 2011-11-22 | Medicine composition containing dehydrogenated corydaline as well as preparation method and measurement method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110372556XA CN102512416A (en) | 2011-11-22 | 2011-11-22 | Medicine composition containing dehydrogenated corydaline as well as preparation method and measurement method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102512416A true CN102512416A (en) | 2012-06-27 |
Family
ID=46283673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110372556XA Pending CN102512416A (en) | 2011-11-22 | 2011-11-22 | Medicine composition containing dehydrogenated corydaline as well as preparation method and measurement method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102512416A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103623064A (en) * | 2013-11-15 | 2014-03-12 | 辽宁中医药大学 | Method for separating and purifying total alkaloids from corydalis tuber |
| CN116602966A (en) * | 2023-05-11 | 2023-08-18 | 华宝民康(广东)医药集团有限公司 | Application of 13-methyl-palmatine in preparation of medicines for resisting myocardial ischemia injury and heart fibrosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101278980A (en) * | 2007-11-27 | 2008-10-08 | 中国医学科学院药用植物研究所 | Rhizoma corydalis quaternary ammonium total alkalis and method of preparing the same |
| CN101288699A (en) * | 2008-06-24 | 2008-10-22 | 中国医学科学院药用植物研究所 | Method for controlling quality of corydalis tuber and preparation thereof and drug effect thereof by using finger print |
-
2011
- 2011-11-22 CN CN201110372556XA patent/CN102512416A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101278980A (en) * | 2007-11-27 | 2008-10-08 | 中国医学科学院药用植物研究所 | Rhizoma corydalis quaternary ammonium total alkalis and method of preparing the same |
| CN101288699A (en) * | 2008-06-24 | 2008-10-22 | 中国医学科学院药用植物研究所 | Method for controlling quality of corydalis tuber and preparation thereof and drug effect thereof by using finger print |
Non-Patent Citations (1)
| Title |
|---|
| 刘生肸，等: "延胡索与川楝子配伍中总生物碱含量变化的研究", 《中医儿科杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103623064A (en) * | 2013-11-15 | 2014-03-12 | 辽宁中医药大学 | Method for separating and purifying total alkaloids from corydalis tuber |
| CN103623064B (en) * | 2013-11-15 | 2015-12-30 | 辽宁中医药大学 | A kind of isolation and purification method of Rhizoma Corydalis total alkaloids |
| CN116602966A (en) * | 2023-05-11 | 2023-08-18 | 华宝民康(广东)医药集团有限公司 | Application of 13-methyl-palmatine in preparation of medicines for resisting myocardial ischemia injury and heart fibrosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102133256B (en) | Rhodiola crenulata extract and preparation method thereof | |
| CN101984983B (en) | Detection method of Lamiophlomis rotata extract, medicine composition containing the extract | |
| CN102772499B (en) | Effective parts obtained by alcohol extraction of raw materials of Relingqing granules as well as preparation method and applications thereof | |
| CN101323618B (en) | Method for separating and preparation of Gelsemium elegans alkaloid monomer by high speed counter current chromatography | |
| CN101274025A (en) | Chinese medicinal composition with functions of reducing fever, purging the intense heat and detoxicating and preparation method thereof and quality control method | |
| CN103823034A (en) | Honeysuckle contrasting extract and preparation method thereof | |
| CN103926332B (en) | A kind of Ultra Performance Liquid Chromatography method of uridine, guanosine and adenosine content in Simultaneously test pinellia tuber extract | |
| CN101057890B (en) | Traditional Chinese medicinal composition for treating coronary heart disease and its preparation method, preparations and its application | |
| CN1289470C (en) | Process for rapid preparation of high pure pharmaceutical matters from patrinia villosa juss | |
| CN104829666A (en) | Method for preparing high purity baicalin from radix scutellariae | |
| CN103301177B (en) | The preparation of Mahonia dolichostylis total alkaloids and method of quality control thereof | |
| CN102512416A (en) | Medicine composition containing dehydrogenated corydaline as well as preparation method and measurement method | |
| CN102702289A (en) | Method for purifying three types of flavonoid glycosides from large-leaf poacynum leaves by applying high-speed counter-current chromatography | |
| CN103340916A (en) | Lindley eupatorium extract as well as preparation method and application thereof | |
| CN101559066B (en) | Use of beta-galactosides and composition in preparing medicine for myocardial ischemia | |
| CN103721148A (en) | Sharpleaf galangal fruit composition for treatment of acute or chronic gastroenteritis and preparation method thereof | |
| CN103142474B (en) | With the composition and method of making the same that high purity bilobalide B is active component | |
| CN103239487A (en) | Bilobalide injection and content determination method | |
| CN103145729B (en) | Bilobalide B compound and preparation method thereof | |
| CN102140101A (en) | Method for preparing Herperione, application thereof, capsule thereof, preparation method and application of capsule | |
| CN102397308B (en) | Preparation process of hypnagogic active component of fructus cnidii | |
| CN104027403A (en) | Method for preparing polygala glycolipid effective part | |
| CN102093210A (en) | Purified preparation method of six ginkgoic acid monomers | |
| CN102060853B (en) | Method for separating alkaloid by reversely two-way eluted pH-zone-refining counter-current chromatography | |
| CN102641347A (en) | Red paeony root extract, as well as preparation and application methods thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120627 |